Interestingly, besides KRAS/NRAS wildtype status (40%/93.3% of SARIFA-positive patients in our cohort), which is already an approved biomarker for cetuximab therapy, CD56+ cell infiltration has already been linked to response to cetuximab therapy in CRC patients [40]. The gene discussed is KRAS; the disease is colorectal carcinoma.